A flood of cheap copies of Novo Nordisk A/S’ blockbuster weight-loss drug in India is already reshaping the country’s fast-growing obesity medicine market, showing how quickly the patent cliff will affect GLP-1 makers like Eli Lilly & Co.

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." (Source: Bloomberg)

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close." (Source: Bloomberg)

Earlier this year, Novo Nordisk A/S pulled off the best obesity-drug launch ever with its Wegovy pill. Now it’s focused on building on more than 600,000 prescriptions as Eli Lilly & Co. threatens to siphon patients away with a new pill of its own.

Hims & Hers Health Inc. shares posted their best week on record as a new partnership with Novo Nordisk A/S fuels fresh optimism about the company’s future in weight-loss drugs.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec. (Source: Bloomberg)

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

Denmark’s economy is poised to expand at the fastest pace in the Nordic region this year, even as pharmaceutical giant Novo Nordisk A/S grapples with slowing sales, according to the country’s largest lender.

Novo Nordisk A/S will spend €432 million ($507 million) upgrading an Irish factory to produce its hit Wegovy weight-loss pill for markets outside the US, the Irish Times reported Monday.

The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Kristine Aquino, Carol Massar and Tim Stenovec. (Source: Bloomberg)

Novo Nordisk A/S plans to slash the US list prices for its blockbusters Wegovy and Ozempic next year as the drugmaker struggles to claw back a larger share of the obesity market.

An experimental drug Novo Nordisk licensed last year has shown notable weight loss in a mid-stage study in China, boosting the company’s search for newer products that could sustain its growth in the obesity market.

Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda. (Source: Bloomberg)

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Disappointing data from Novo Nordisk A/S is sending shockwaves across equities in Denmark, dragging the wider market down and underscoring how tightly the country’s fortunes are tied to the obesity-drug maker.

Quantum investment firm Quantonation Ventures has raised €220 million ($260 million) for its second fund devoted to physics-based technologies, backed by data center builder ACS SA and Novo Nordisk A/S’s controlling shareholder, among others.

Novo Nordisk says it’s investing in production in central Ireland, doing battle with Eli Lilly

Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg’s Katie Greifeld to discuss GLP-1 supply, pricing and the company’s lawsuit against Hims over alleged obesity drug copycats. (Source: Bloomberg)

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are TIAA Wealth Management’s Niladri Mukherjee, Quest Diagnostics’s Jim Davis, Baird’s Michael Ha, BD’s Tom Polen, Charles Schwab’s Kevin Gordon, Cox Automotive’s Stephanie Valdez Streaty, Hinge Health’s Daniel Perez, Philips’ Roy Jakobs, Willkie Farr & Gallagher’s Edward Best, and ESPN’s Patrick McEnroe. (Source: Bloomberg)